This week Alba Therapeutics announced its first European member of its phase 2 clinical trial of a medicine that could help treat patients with celiac disease. The company is actively seeking participants in this phase of the study. Alba Therapeutics claims this medicine could reduce the “leaky gut” issue that researchers say may contribute to celiac disease. Current treatment for celiac disease is strict adherence to a gluten-free diet.
You can find more specifics on this part of the trial the latest information at Alba Therapeutics.